Prevention of Epidermal Growth Factor Receptor Inhibitor-Associated Dermatologic Toxicities by Pre-treatment With Topical Tretinoin
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Medication Reaction
Both
Medication Reaction
Trial Information
Prevention of Epidermal Growth Factor Receptor Inhibitor-Associated Dermatologic Toxicities by Pre-treatment With Topical Tretinoin
Inclusion Criteria:
- Age 18 years or over
- Scheduled to begin treatment with an EGFR inhibitor drug
Exclusion Criteria:
- Pregnant or nursing
- History of bleeding disorder
- History of keloids or large, thick, puffy-looking scars in the last 10 years
- Used topical retinoids in the last year (e.g. tretinoin/Retin-A, adapalene/Differin,
tazarotene/Tazorac)
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Outcome Measure:
EGFRi rash severity
Outcome Time Frame:
8 weeks
Safety Issue:
No
Authority:
United States: Johns Hopkins Medicine IRB
Study ID:
NA_00042104
NCT ID:
NCT01349556
Start Date:
May 2011
Completion Date:
December 2013
Related Keywords:
- Medication Reaction
- cancer
- chemotherapy
- EGFR inhibitors
- tretinoin
- EGFRi drug rash
- Drug Toxicity
Name | Location |
|---|---|
| Johns Hopkins Dept. of Dermatology | Baltimore, Maryland 21287 |
